Articles from EverythingALS

Lou Gehrig Day — EverythingALS, a nonprofit dedicated to accelerating research, technology, and patient access for amyotrophic lateral sclerosis (ALS), and Vision 2030 are partnering with the Allen Institute to accelerate research into ALS disease progression and to identify new targets that could form the basis for novel medicines to treat the disease. This ALS-focused research will be supported by EverythingALS and Vision 2030’s $1M initial investment in the newly launched Allen Institute’s Brain Health Accelerator. The Allen Institute has committed $200M to the Brain Health Accelerator, a research initiative to study neurodegenerative diseases.

EverythingALS, the patient-focused nonprofit leveraging technology and data science to accelerate care and research for ALS, today announced the launch of SAVA, an AI-powered clinical trial matching tool that connects ALS patients with clinical trials they may qualify for.

SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- EverythingALS is proud to announce the launch of its new mobile app, now available on both the iOS and Android marketplaces. This app represents a significant upgrade from the previous version, which was designed exclusively for observational study research participants. The new EverythingALS app not only retains its research capabilities but also expands to serve the broader ALS community with enhanced features and services.

Vision 2030 will utilize advanced technologies and an innovative operating model for research and drug development

Data from the citizen-driven initiative is made public for the first time

SEATTLE, Sept. 27, 2023 (GLOBE NEWSWIRE) -- EverythingALS, a citizen science research organization dedicated to developing cure for ALS, announced today the Student Fellow Scholarship Awards and the expansion and continued enrollment of student Ambassadors program. Both programs are core pillars of the EverythingALS Care to Cure™ impact model.

EverythingALS today announced it has received $400,000 from ALS Finding a Cure® and The ALS Association to support studies for the identification of early digital diagnostic markers of ALS. The NeuroLens digital diagnostics program is a unique partnership with diverse and multidisciplinary research teams formed between - EverythingALS, a citizen led nonprofit research organization dedicated to changing the paradigm for ALS through AI/ML, digital monitoring and open innovation, and the Sean. M. Healey and AMG Center for ALS at Massachusetts General Hospital (MGH) with a goal of identifying the earliest signs of ALS in order to enable intervention as soon as possible by monitoring pre-symptomatic ALS gene carriers.

EverythingALS and CureALS, two prominent organizations dedicated to finding a cure for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), are thrilled to announce their merger and unified operations on the EverythingALS platform. This groundbreaking collaboration combines the expertise, resources, and strategic plans of both organizations and solidifies our commitment to caring for people with ALS, researcher support, public/private partnership, data innovation and the use of artificial intelligence (AI) technology to drive citizen-driven research with open innovation as the core of the program.